Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center.

ISRN urology Pub Date : 2012-01-01 Epub Date: 2012-03-20 DOI:10.5402/2012/391705

Olivier Riou, Pascal Fenoglietto, Benoit Laliberté, Cathy Menkarios, Carmen Llacer Moscardo, Meng Huor Hay, Norbert Ailleres, Jean-Bernard Dubois, Xavier Rebillard, David Azria

{"title":"Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center.","authors":"Olivier Riou, Pascal Fenoglietto, Benoit Laliberté, Cathy Menkarios, Carmen Llacer Moscardo, Meng Huor Hay, Norbert Ailleres, Jean-Bernard Dubois, Xavier Rebillard, David Azria","doi":"10.5402/2012/391705","DOIUrl":null,"url":null,"abstract":"<p><p>Background. To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome. Patients and Methods. 57 patients were treated with salvage IMRT to the prostate bed in our center from January, 2007, to February, 2010. The mean prescription dose was 68 Gy in 34 fractions. Forty-four patients received concomitant androgen deprivation. Results. Doses to organs at risk were low without altering target volume coverage. Salvage IMRT was feasible without any grade 3 or 4 acute gastrointestinal or urinary toxicity. With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥2 rectal late toxicities were reported. Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression and 7.7% (1/13) without). Conclusion. Salvage IMRT is feasible and results in low acute and chronic side-effects. Longer follow-up is warranted to draw conclusions in terms of oncologic control.</p>","PeriodicalId":89401,"journal":{"name":"ISRN urology","volume":"2012 ","pages":"391705"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/391705","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5402/2012/391705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/3/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

Abstract

Background. To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome. Patients and Methods. 57 patients were treated with salvage IMRT to the prostate bed in our center from January, 2007, to February, 2010. The mean prescription dose was 68 Gy in 34 fractions. Forty-four patients received concomitant androgen deprivation. Results. Doses to organs at risk were low without altering target volume coverage. Salvage IMRT was feasible without any grade 3 or 4 acute gastrointestinal or urinary toxicity. With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥2 rectal late toxicities were reported. Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression and 7.7% (1/13) without). Conclusion. Salvage IMRT is feasible and results in low acute and chronic side-effects. Longer follow-up is warranted to draw conclusions in terms of oncologic control.

Abstract Image

查看原文本刊更多论文

前列腺癌的三年补救性IMRT:蒙彼利埃癌症中心的结果。

背景。评估补救性调强放射治疗(IMRT)的可行性，并检查临床结果。患者与方法:2007年1月至2010年2月，本院对57例前列腺床行补救性IMRT治疗。平均处方剂量为68 Gy，分34个剂型。44例患者同时接受雄激素剥夺。结果。在不改变靶体积覆盖范围的情况下，对危险器官的剂量很低。挽救性IMRT是可行的，没有任何3级或4级急性胃肠道或泌尿毒性。中位随访21个月，报告了1例2级尿毒性和1例≥2级直肠晚期毒性。生物学无复发生存率为96.5%(2.3%(1/44)有雄激素抑制复发，7.7%(1/13)无)。结论。挽救性IMRT是可行的，急性和慢性副作用低。为了得出肿瘤控制方面的结论，需要更长时间的随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ISRN urology

自引率

0.00%

发文量